Serranator POINT FORCE Registry
for Peripheral Artery Disease (PAD)
18 locations incl. Scottsdale
Sponsor: Cagent Vascular LLC
Sex: All·Age: 18+
Code: NCT06687590·Recruiting·Listed Nov 2024
Miami Valley Hospital
Clinical research site in Dayton, Ohio · ONE WYOMING STREET, DAYTON, OH 45409-2793 · (937) 208-8000 · Website
Part of Miami Valley Hospital
As of July 2026, 45 paid clinical trials are recruiting at Miami Valley Hospital in Dayton, Ohio. Active studies at this site cover conditions such as Stage IV Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8 and Anatomic Stage II Breast Cancer AJCC v8. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Recruiting clinical trials at Miami Valley Hospital (45)
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
for Breast Cancer
1105 locations incl. Anchorage
Sponsor: NRG Oncology
Sex: Female·Age: 18 - 60
Code: NCT05879926·Phase 3·Recruiting·Listed May 2023
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
for Stage III Colon Cancer
922 locations incl. Fairhope
Sponsor: NRG Oncology
Sex: All·Age: 18+
Code: NCT05174169·Phase 2, Phase 3·Recruiting·Listed Dec 2021
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
for Locally Advanced Cervical Adenocarcinoma
289 locations incl. Birmingham
Sponsor: National Cancer Institute (NCI)
Sex: Female·Age: 18+
Code: NCT07061977·Phase 3·Recruiting·Listed Jul 2025
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
for Anatomic Stage I Breast Cancer AJCC v8
585 locations incl. Phoenix
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All·Age: 18+
Code: NCT06876714·Phase 3·Recruiting·Listed Mar 2025
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
for Advanced Esophageal Adenocarcinoma
643 locations incl. Anchorage
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All·Age: 18+
Code: NCT05677490·Phase 3·Recruiting·Listed Jan 2023
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
for Head and Neck Squamous Cell Carcinoma
466 locations incl. Anchorage
Sponsor: ECOG-ACRIN Cancer Research Group
Sex: All·Age: 18+
Code: NCT02734537·Phase 2·Recruiting·Listed Apr 2016
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
for Advanced Lung Non-Squamous Non-Small Cell Carcinoma
326 locations incl. Anchorage
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18+
Code: NCT04181060·Phase 3·Recruiting·Listed Nov 2019
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
for Lung Non-Small Cell Carcinoma
640 locations incl. Anchorage
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18+
Code: NCT04267848·Phase 3·Recruiting·Listed Feb 2020
Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects
for Malignancy
405 locations incl. Anchorage
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All·Age: All ages
Code: NCT04242095·Recruiting·Listed Jan 2020
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
for Smoldering Plasma Cell Myeloma
488 locations incl. Birmingham
Sponsor: ECOG-ACRIN Cancer Research Group
Sex: All·Age: 18+
Code: NCT03937635·Phase 3·Recruiting·Listed May 2019
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
for Adenocarcinoma of the Colon
365 locations incl. Fairbanks
Sponsor: NRG Oncology
Sex: All·Age: 45 - 70
Code: NCT05080673·Recruiting·Listed Oct 2021
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
for Extensive Stage Lung Small Cell Carcinoma
273 locations incl. Anchorage
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18+
Code: NCT04402788·Phase 2, Phase 3·Recruiting·Listed May 2020
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
for Anatomic Stage II Breast Cancer AJCC v8
525 locations incl. Birmingham
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18+
Code: NCT06058377·Phase 3·Recruiting·Listed Sep 2023
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
for Previously Treated Non-Small Cell Lung Cancer
950 locations incl. Birmingham
Sponsor: SWOG Cancer Research Network
Sex: All·Age: 18+
Code: NCT03851445·Phase 2, Phase 3·Recruiting·Listed Feb 2019
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
for Pancreatic Acinar Cell Carcinoma
261 locations incl. Kingman
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18+
Code: NCT04858334·Phase 2·Recruiting·Listed Apr 2021
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
for Advanced Malignant Solid Neoplasm
430 locations incl. Birmingham
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: All ages
Code: NCT05564377·Phase 2·Recruiting·Listed Oct 2022
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
for Clear Cell Renal Cell Carcinoma
405 locations incl. Phoenix
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All·Age: 18+
Code: NCT06661720·Phase 3·Recruiting·Listed Oct 2024
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
for Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma
316 locations incl. Gilbert
Sponsor: NRG Oncology
Sex: All·Age: 18+
Code: NCT06958328·Phase 3·Recruiting·Listed May 2025
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
for Advanced Lung Non-Small Cell Carcinoma
266 locations incl. Fayetteville
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 70+
Code: NCT06096844·Phase 3·Recruiting·Listed Oct 2023
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
for Locally Advanced Lung Non-Small Cell Carcinoma
446 locations incl. Birmingham
Sponsor: NRG Oncology
Sex: All·Age: 18+
Code: NCT05624996·Phase 3·Recruiting·Listed Nov 2022
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
for Lung Non-Small Cell Carcinoma
263 locations incl. Jonesboro
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18+
Code: NCT06498635·Phase 3·Recruiting·Listed Jul 2024
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
for Recurrent Lung Non-Small Cell Carcinoma
372 locations incl. Daphne
Sponsor: SWOG Cancer Research Network
Sex: All·Age: 18+
Code: NCT05642572·Phase 2·Recruiting·Listed Dec 2022
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
for Metastatic Renal Cell Carcinoma
280 locations incl. Kingman
Sponsor: NRG Oncology
Sex: All·Age: 18+
Code: NCT05327686·Phase 2·Recruiting·Listed Apr 2022
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
for Renal Pelvis and Ureter Urothelial Carcinoma
152 locations incl. Kingman
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18+
Code: NCT04628767·Phase 2, Phase 3·Recruiting·Listed Nov 2020
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
for Recurrent Endometrial Carcinoma
285 locations incl. Birmingham
Sponsor: National Cancer Institute (NCI)
Sex: Female·Age: 18+
Code: NCT05554328·Phase 2·Recruiting·Listed Sep 2022
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
for Locally Advanced Pancreatic Adenocarcinoma
272 locations incl. Anchorage
Sponsor: SWOG Cancer Research Network
Sex: All·Age: 18+
Code: NCT06998940·Phase 3·Recruiting·Listed May 2025
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
for Advanced Esophageal Adenocarcinoma
346 locations incl. Little Rock
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18+
Code: NCT06203600·Phase 2, Phase 3·Recruiting·Listed Jan 2024
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study
for Metastatic Colorectal Adenocarcinoma
164 locations incl. Kingman
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All·Age: 18+
Code: NCT05673148·Phase 3·Recruiting·Listed Jan 2023
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
for Malignant Female Reproductive System Neoplasm
177 locations incl. Birmingham
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18+
Code: NCT06126276·Phase 2·Recruiting·Listed Nov 2023
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
for Metastatic Dedifferentiated Liposarcoma
241 locations incl. DeKalb
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18+
Code: NCT06422806·Phase 3·Recruiting·Listed May 2024
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
for Metastatic Head and Neck Squamous Cell Carcinoma
170 locations incl. Little Rock
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18+
Code: NCT06589804·Phase 3·Recruiting·Listed Sep 2024
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
for Stage I Breast Cancer
707 locations incl. Mobile
Sponsor: NRG Oncology
Sex: All·Age: 50 - 70
Code: NCT04852887·Phase 3·Recruiting·Listed Apr 2021
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
for Recurrent Lung Non-Small Cell Carcinoma
381 locations incl. Daphne
Sponsor: SWOG Cancer Research Network
Sex: All·Age: 18+
Code: NCT06616584·Phase 2, Phase 3·Recruiting·Listed Sep 2024
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
for Recurrent Lung Non-Small Cell Carcinoma
241 locations incl. Daphne
Sponsor: SWOG Cancer Research Network
Sex: All·Age: 18 Minutes+
Code: NCT06031688·Phase 2·Recruiting·Listed Sep 2023
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
for Rectal Cancer
103 locations incl. Phoenix
Sponsor: Canadian Cancer Trials Group
Sex: All·Age: 18+
Code: NCT06205485·Phase 3·Recruiting·Listed Jan 2024
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
for Anatomic Stage IV Breast Cancer AJCC v8
586 locations incl. Anchorage
Sponsor: SWOG Cancer Research Network
Sex: All·Age: 18+
Code: NCT03723928·Recruiting·Listed Oct 2018
DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes
for Gestational Diabetes Mellitus
21 locations incl. Tuscaloosa
Sponsor: Ohio State University
Sex: Female·Age: 18+
Code: NCT06445946·Phase 4·Recruiting·Listed Jun 2024
Intranasal Sphenopalatine Ganglion Blockade for Headaches Following Aneurysmal Subarachnoid Hemorrhage
for Aneurysmal Subarachnoid Hemorrhage (aSAH)
1 location in Dayton
Sponsor: Wright State University
Sex: All·Age: 18+
Code: NCT07116408·Phase 4·Recruiting·Listed Aug 2025
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
for Ovarian Carcinoma
473 locations incl. Birmingham
Sponsor: NRG Oncology
Sex: Female·Age: 35 - 50
Code: NCT04251052·Recruiting·Listed Jan 2020
Showing the 40 most relevant of 45 recruiting trials at this site. Browse all with filters →
More research sites in Dayton
- Miami Valley Hospital North (42 trials)
- Dayton Children's Hospital (34 trials)
- Premier Blood and Cancer Center (33 trials)
- Dayton Physician LLC - Englewood (11 trials)
- META Medical Research Institute (5 trials)
- Dayton Physician LLC-Miami Valley Hospital North (4 trials)
- Clinical Trial Site (3 trials)
- Orthopedic Associates of Southwest Ohio (3 trials)
- Dayton Physicians Network (3 trials)
- Dayton VA Medical Center (3 trials)